Structure Search


    Online Support

  •  Customer service

    Location: Industrial Info

CAS:26239-55-4| The Application of ADA in Biomedical Technology

2023-11-17 来源:转载自第三方

Product Name:ADA
Molecular Formula:C6H10N2O5
Article No.:    Y0040
Structural Formula:

Product Introduction
ADA is a yellow to orange red crystalline powder with dual effects of bleaching and oxidation. ADA is mainly used as a fast processing agent for flour, as well as a desulfurizer for water gas and semi water gas in the production of synthetic ammonia, a dye intermediate, and a biological buffer.
Application of ADA
Y-27632 is an efficient, cell permeable, reversible, and selective Rho related protein kinase inhibitor. Its functions mainly include: (1) selectively inhibiting calcium ion sensitivity of smooth muscle and blocking its contraction, preventing Rho induced and p160ROCK mediated cell tension fiber formation; (2) Reduce blood pressure in several hypertensive rat models; (3) Protect Ehrlich ascites cancer mice from tumor formation; (4) Prevent intrahepatic metastasis of liver cancer.
Classic hallucinogens have the effect of improving depression, anxiety, and nicotine addiction. However, the hallucination phenomenon induced by classical hallucinogens is one of the main obstacles to its clinical application. Therefore, how to suppress or reduce the hallucination effect while ensuring the therapeutic effect of classical hallucinogens is an important issue that needs to be solved in this field. At present, there are no reports on reagents that specifically inhibit hallucination, and the molecular mechanism of classical hallucinogens activating the 5-HT2A receptor to induce hallucination is still unclear. It is urgent to discover the specific molecular mechanism and target of classical hallucinogens inducing hallucination, in order to specifically suppress hallucination and develop drugs that can be used for specific inhibition of hallucination. Therefore, the CN115998736A patent developed a Y-27632 substance for inhibiting hallucinations. The drug composition includes a buffer, carrier, and/or excipient. The buffer can be MOPS, MOPSO, MOBS, Tris, Hepes, HEPBS, MES, phosphate, carbonate, acetate, citrate, glycolate, lactate, borate, ACES, ADA, etc.
Y-27632 in this patent can specifically inhibit hallucinogenic effects and can be used to reduce the side effects and adverse reactions of classic hallucinogens in the treatment or improvement of other mental disorders such as depression and anxiety. Especially, it has good application prospects in reducing the hallucinogenic effects caused by classic hallucinogens.

CN115998736A Application of Y-27632 in Specific Inhibition of Hallucination.